151 related articles for article (PubMed ID: 38329007)
1. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
Ritchie M; Salazar CR; Gillen DL; Grill JD
Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
[TBL] [Abstract][Full Text] [Related]
2. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
3. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
Molina-Henry DP; Raman R; Liu A; Langford O; Johnson K; Shum LK; Glover CM; Dhadda S; Irizarry M; Jimenez-Maggiora G; Braunstein JB; Yarasheski K; Venkatesh V; West T; Verghese PB; Rissman RA; Aisen P; Grill JD; Sperling RA
Alzheimers Dement; 2024 Jun; 20(6):3827-3838. PubMed ID: 38629508
[TBL] [Abstract][Full Text] [Related]
4. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial.
Raman R; Quiroz YT; Langford O; Choi J; Ritchie M; Baumgartner M; Rentz D; Aggarwal NT; Aisen P; Sperling R; Grill JD
JAMA Netw Open; 2021 Jul; 4(7):e2114364. PubMed ID: 34228129
[TBL] [Abstract][Full Text] [Related]
5. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
6. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Grill JD; Flournoy C; Dhadda S; Ernstrom K; Sperling R; Molina-Henry D; Tranotti K; Harris R; Kanekiyo M; Gee M; Irizarry M; Kramer L; Aisen P; Raman R
Ann Neurol; 2024 Feb; 95(2):288-298. PubMed ID: 37830926
[TBL] [Abstract][Full Text] [Related]
7. Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review.
Lim AC; Barnes LL; Weissberger GH; Lamar M; Nguyen AL; Fenton L; Herrera J; Han SD
Commun Med (Lond); 2023 Jul; 3(1):101. PubMed ID: 37491471
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study.
Ruthirakuhan M; Wood Alexander M; Cogo-Moreira H; Robinson T; Amariglio R; Buckley RF; Sperling RA; Swardfager W; Black SE; Rabin JS
J Prev Alzheimers Dis; 2024; 11(1):48-55. PubMed ID: 38230716
[TBL] [Abstract][Full Text] [Related]
9. Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.
Ryan MM; Gillen DL; Grill JD
Ann Clin Transl Neurol; 2021 Aug; 8(8):1646-1655. PubMed ID: 34227249
[TBL] [Abstract][Full Text] [Related]
10. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
11. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
[TBL] [Abstract][Full Text] [Related]
12. Anticipated reactions to learning Alzheimer's disease biomarker results.
Clark LR; Erickson CM; Jonaitis EM; Ma Y; Chin NA; Basche K; Ketchum FB; Gleason CE
Alzheimers Res Ther; 2022 Jun; 14(1):85. PubMed ID: 35733219
[TBL] [Abstract][Full Text] [Related]
13. Is Our Science Representative? A Systematic Review of Racial and Ethnic Diversity in Orthopaedic Clinical Trials from 2000 to 2020.
Cwalina TB; Jella TK; Manyak GA; Kuo A; Kamath AF
Clin Orthop Relat Res; 2022 May; 480(5):848-858. PubMed ID: 34855650
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.
Erickson CM; Chin NA; Rosario HL; Peterson A; Johnson SC; Clark LR
Alzheimers Dement (N Y); 2023; 9(3):e12413. PubMed ID: 37521522
[TBL] [Abstract][Full Text] [Related]
15. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know.
Erickson CM; Chin NA; Johnson SC; Gleason CE; Clark LR
Alzheimers Dement (Amst); 2021; 13(1):e12150. PubMed ID: 33665341
[TBL] [Abstract][Full Text] [Related]
16. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Grill JD; Zhou Y; Elashoff D; Karlawish J
Neurobiol Aging; 2016 Mar; 39():147-53. PubMed ID: 26923411
[TBL] [Abstract][Full Text] [Related]
17. Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.
Grill JD; Cox CG; Harkins K; Karlawish J
Alzheimers Res Ther; 2018 Dec; 10(1):125. PubMed ID: 30579361
[TBL] [Abstract][Full Text] [Related]
18. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
Cassidy MR; Roberts JS; Bird TD; Steinbart EJ; Cupples LA; Chen CA; Linnenbringer E; Green RC
Alzheimers Dement; 2008 Nov; 4(6):406-13. PubMed ID: 19012865
[TBL] [Abstract][Full Text] [Related]
19. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
[TBL] [Abstract][Full Text] [Related]
20. Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity.
Gillis C; Montenigro P; Nejati M; Maserejian N
Alzheimers Dement; 2023 May; 19(5):1841-1848. PubMed ID: 36322470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
